Fig. 3: SRPK1 ablation mediates tumor growth inhibition in EGFR mutant tumors in vivo. | Oncogene

Fig. 3: SRPK1 ablation mediates tumor growth inhibition in EGFR mutant tumors in vivo.

From: Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer

Fig. 3

A Subcutaneous tumors at the experimental endpoint. B Growth curves of xenograft tumors derived from PC9-vector, PC9-SRPK1, PC9GR-Vector, and PC9GR-SRPK1-sh2# cells in mice treated with gefitinib (n = 5). C IHC analysis of SRPK1 and cleaved caspase 3 levels in xenograft tumors derived from PC9-vector and PC9-SRPK1 and (D) PC9GR-Vector and PC9GR-SRPK1-sh2# cells in mice treated with gefitinib. Statistical analysis of staining is provided. Data represent the mean optical density (MOD) ± SD (n = 10). The whiskers represent 5 and 95 percentiles. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page